Covaxin effectively neutralizes alpha, delta variants: US top body

Covaxin effectively neutralizes alpha, delta variants: US top body

WASHINGTON: The COVID-19 jab of Covaxin, developed and manufactured by Hyderabad-based Bharat Biotech, generates antibodies that can effectively neutralize alpha (B117) and delta (B1617) variants of SARS-CoV-2, the virus that causes COVID-19. Causes 19. The US National Institutes of Health cites the results of two studies of blood serum of people who received the shots.
Covaxin contains a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.
An adjuvant developed by the agency has also contributed to the success of the highly efficacious Covaxin COVID-19 vaccine, which has been received by nearly 25 million people in India and elsewhere, the NIH said.
Adjuvants are substances that are formulated as part of a vaccine to boost the immune response and increase the effectiveness of the vaccine.
“Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
“I am delighted that Adjuvant, a novel vaccine developed in the United States with NIAID support, is part of an effective COVID-19 vaccine available to people in India,” he said.
Covaxin – the adjuvant used in Alhydroxiquim-II – was discovered and tested in the laboratory by ViroVax LLC, a biotech company in Lawrence, Kansas, with particular support from the NIAID Adjuvant Development Program.
The adjuvant consists of a small molecule attached in a unique way to the alhydrogel, often called alum, which is the most commonly used adjuvant in vaccines for people.
Lhydroxyzyme-II travels to the lymph nodes, where the small molecule dissociates from the alum and activates two cellular receptors. These receptors, TLR7 and TLR8, play an important role in the immune response to the virus. Lhydroxyzyme-II is the first adjuvant in a vaccine authorized against an infectious disease to activate TLR7 and TLR8.
Molecules that activate TLR receptors potently stimulate the immune system, but the side effects of alhydroxyzyme-II are mild. This is because, after Covaxin is injected, the adjuvant travels directly to nearby lymph nodes, which contain white blood cells that play an essential role in identifying pathogens and fighting infection.
Covaxin’s Phase II trial results suggest it is safe and well-tolerated, while unpublished interim results from Phase III trials indicate that the vaccine has 78 percent efficacy against symptomatic, severe COVID-19. There is 100 percent efficacy against 19, including hospitalization, and 70 percent efficacy against asymptomatic infection with SARS-CoV-2.
Bharat Biotech signed a licensing agreement with Virovax in 2019 to use Lhydroxycim-II in its candidate vaccines. This license was expanded during the COVID-19 pandemic to include Covaxin, which has received emergency use authorization in India and over a dozen other countries.
Bharat Biotech has developed Covaxin in collaboration with the Indian Council of Medical Research-National Institute of Virology. Bharat Biotech expects to produce an estimated 700 million doses of Covaxin by the end of 2021.

STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ

Leave a Reply

Your email address will not be published. Required fields are marked *